-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
February 2023
-
CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says
In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC.
-
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?
Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials.
-
TTLC 2023 Showcases Early Ongoing Trial Data, Newest Therapies
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN.
-
Patient Perspective: Me, Myself, and Scanxiety
Studies that don’t show survival benefit with more frequent surveillance won’t convince patients they’re better off without scans. Even if regularly scheduled scans don’t help patients live longer, they do help them live better.
-
In Brief for Feb. 22, 2023
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership.
-
Multifaceted Approach Needed for Early Lung Cancer Detection
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap.
-
Increasing Evidence Demonstrates the Usefulness of ctDNA
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection.
-
Education Award Recipients Recognized at Latin America Conference
During the Closing Ceremony, five early-career, trainee, or resident investigators were honored for presenting at LALCA 2023.
-
Committee Update: Advocates Offer Unique Support to Members, Help Investigators Understand Patients
Patient Advocates Committee Chair Jill Feldman said ensuring the patient voice is present in research helps to improve the work being done to reduce the burden of lung cancer worldwide.
-
In Brief for Feb. 8, 2023
Dr. Carolyn Dresler Joins Action on Smoking and Health (ASH) Board of Trustees; Novel Liquid Biopsy Assay for Lung Carcinoma Detection Receives FDA Breakthrough Device Designation.